Concurrent pediatric eosinophilic esophagitis and inflammatory bowel disease: a longitudinal single center case‒control study and literature review.

COI Statement

Declarations. Ethical approval: This study received ethics approval at Seattle Children’s Hospital (IRB#00004337). Conflict of interest: No financial or non-financial benefits have been received or will be received from any party directly or indirectly to this subject of this article. The authors have no conflict of interest to declare.

References:

• Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266.
• Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401:1878–90.
• Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Singh H, Otley AR, et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am J Gastroenterol. 2017;112:1120–34.
• Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165:1197–205.
• Muir A, Falk GW. Eosinophilic esophagitis: a review. JAMA. 2021;326:1310–8.